Home > News & Events > Press Releases > Full Press Announcement: Rhenovia Pharma and Rhenovia Development Inc. announce the launch of new drug research programs for Huntington disease and Duchenne muscular dystrophies
30 March 2012 - Full Press Announcement: Rhenovia Pharma and Rhenovia Development Inc. announce the launch of new drug research programs for Huntington disease and Duchenne muscular dystrophies
Rhenovia Pharma SAS (Mulhouse, France) and Rhenovia Development Inc. (Cambridge, MA, USA)
In a recent world wide press release, Rhenovia has announced the launch of new drug research programs targeting rare diseases.
Rhenovia is willing to extend its modeling & simulation expertise at first to Huntington disease or Duchenne muscular dystrophies two diseases of high and urgent medical need. Rhenovia biosimulation approach and breakthrough technology revealed particularly suited to understand the highly complex biological mechanisms underlying the very broad spectrum of symptoms affecting motor, mental and cognitive functions.
Please find below the full version of the press release. We would be pleased to provide you with further information about our service-partnership offerings. Please contact Dr. Serge Bischoff at email@example.com
Note also that Rhenovia will be present at the 2012 BIO International Convention, Boston, MA, USA, 18-21 June 2012. You can already propose meeting us at firstname.lastname@example.org